Skip to content
KVUE

Kenvue Inc.

Kenvue Inc. Q2 FY2025 earnings call

August 7, 2025 · fiscal period ended 2025-06

EPS · actual vs est

$0.29 / $0.28Beat +2.9%

Revenue · actual vs est

$3.84B / $3.85BMiss -0.4%
Ask about this call

Summary

Generated 2025-08-07

Management highlights

  • Kirk Perry introduced as interim CEO, leveraging his experience in CPG, tech, and data analytics. - Company undergoing strategic review of alternatives, including brand portfolio optimization. - Immediate priorities: strengthen leadership and capabilities, review operating strategy, improve execution, review structure and operating model. - Amit Banati focused on operating rigor, efficiencies, revenue growth management, and SG&A optimization to drive consistency and profitability.
View in transcript ↓

Segment performance

Self Care: Organic sales declined 5.9% year-over-year due to lower volumes. In the U.S., 83% of the business held or gained share. Tylenol continued to gain share, and ZYRTEC strengthened its leadership position. Skin Health and Beauty: Organic sales decreased 3.7%. Global consumption stabilized, but there were declines in North America and Asia Pacific. Neutrogena Face showed sequential improvement. Essential Health: Organic sales decreased 2.4%. Wound care brands like BAND-AID grew share, but mouthwash business in the U.S. faced challenges.

View in transcript ↓

Guidance

  • Organic sales expected to be down low single digits in 2025. - Adjusted operating margin expected to contract. - Full-year adjusted diluted EPS range $1 to $1.05, including low single-digit drag from currency.
View in transcript ↓

Risks

  • Self-induced complexity inhibiting agility and results. - Macroeconomic uncertainties impacting category performance. - Retail inventory dynamics and challenges in specific segments like Skin Health and Beauty and mouthwash business.
View in transcript ↓

Q&A highlights

Q: Talked about time frame and complexity, where to focus?

A: Focus on biggest brands, countries, innovations; address self-induced complexity.

Q: Biggest surprises on joining?

A: Surprised by self-induced complexity; excited about pockets of success like Neutrogena Face, EMEA, Lat Am.

Q: How to measure success in restructuring?

A: Measure by sequential improvement in consumer votes, share gains.

Q: Top line guidance and margins?

A: Top line low single-digit decline, margins contracting due to strategic investments, tariffs, etc.

Q: Q3 trends and moving parts?

A: Q3 similar to Q2 trends, seasons weak; guidance incorporates first half results and future factors.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$0.29$0.28+2.9%
Revenue$3.84B$3.85B-0.4%

Transcript

August 7, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.